Malaria vaccine

AHF: Newly Approved Malaria Vaccine Is a Win for Global Health

Retrieved on: 
Thursday, October 5, 2023
AIDS, Public Policy, Government, Health, Healthcare Reform, Infectious Diseases, General Health, Pharmaceutical, AIDS Healthcare Foundation, AHF, Death, Infection, Malaria, Global North and Global South, Malaria vaccine, WHO, Vaccine

AIDS Healthcare Foundation (AHF) applauds the World Health Organization’s (WHO) recommendation of a new malaria vaccine, R21/Matrix-M, for preventing malaria, which disproportionately affects African children.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauds the World Health Organization’s (WHO) recommendation of a new malaria vaccine, R21/Matrix-M, for preventing malaria, which disproportionately affects African children.
  • The affordable and easily deployable vaccine is a welcome step towards vaccinating our world, and Global North countries should help fund the vaccine for equitable distribution.
  • “Once deployed, the new vaccine will help prevent more than 600,000 annual deaths due to malaria, which affects children under age five in Africa most.
  • Now, we must all work together to deliver on the promise this vaccine offers – saving the millions of lives affected by malaria.”

GHIT Fund Announces New Investments: A Total of 2.3 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease and Visceral Leishmaniasis, Vaccine for Malaria and Diagnostics for Tuberculosis

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Infectious diseases, Malaria, Clinical medicine, Tropical diseases, Epidemiology, Vaccination, Malaria vaccine, Vaccines, Antimalarial medication, Vaccine, Parasitism

Targeted vaccination of individuals in high transmission areas promise an immediate and effective reduction in the number of malaria cases.

Key Points: 
  • Targeted vaccination of individuals in high transmission areas promise an immediate and effective reduction in the number of malaria cases.
  • Although a TBV would not directly prevent immunized individuals from developing the disease, it has a clear, delayed clinical benefit for the population.
  • Moreover, a TBV could provide effective means to prevent the spread of antimalarial drug-resistant parasites, and parasites that break through the most advanced malaria vaccine (Mosquirix) to date.
  • Thus, the development of new TBVs is one of the research priorities for a cost-effective intervention that can directly support the malaria eradication effort.

EU Malaria Fund: Sanaria receives substantial investment into its proprietary malaria platform

Retrieved on: 
Sunday, November 15, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Medicine, Infectious diseases, Malaria, Vaccines, Sanaria, Malaria vaccine, PfSPZ Vaccine, Vaccine, COVID-19 vaccine

The EU Malaria Fund has been initiated by kENUP Foundation and is managed by a General Partner under the supervision of Investitionsbank Berlin.

Key Points: 
  • The EU Malaria Fund has been initiated by kENUP Foundation and is managed by a General Partner under the supervision of Investitionsbank Berlin.
  • On November 13, 2020, Sanaria received 12.9M for the development of two malaria vaccines, one malaria prophylactic, as well as an initial proof-of-concept for an oral SARS-CoV-2 vaccine.
  • Sanarias PfSPZ Vaccine is a radiation-attenuated whole-organism vaccine, meaning it is a weakened form of the parasite that causes malaria.
  • Holm Keller, Co-Managing Director of EUMF and Chairman of kENUP Foundation said: Sanaria has developed one of the most advanced malaria vaccine candidates worldwide.

Novavax and Serum Institute of India Announce Development and Commercial Collaboration

Retrieved on: 
Thursday, August 6, 2020
Medical specialties, Health care, Pharmaceutical companies, Vaccines, Novavax, Malaria, Adar Poonawalla, Vaccine, Serum Institute of India, Malaria vaccine, COVID-19 vaccine

As the worlds largest vaccine manufacturer in terms of doses delivered, Serum Institute is the ideal partner to advance NVXCoV2373 throughout India and the LMIC countries.

Key Points: 
  • As the worlds largest vaccine manufacturer in terms of doses delivered, Serum Institute is the ideal partner to advance NVXCoV2373 throughout India and the LMIC countries.
  • For LMICs and India, Novavax and SIIPL are partnering on clinical development, co-formulation, filling and finishing and commercialization of NVX-CoV2373.
  • Novavax will provide to SIIPL both vaccine antigen and MatrixM adjuvant, and Novavax and SIIPL are in discussions to have SIIPL manufacture vaccine antigen in India.
  • Given our experience with Novavax on the development of a malaria vaccine, we know the power of their vaccine technologies, said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.

OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon

Retrieved on: 
Monday, July 13, 2020
Immunology, Immune response, Humoral immunity, Cell-mediated immunity, Immunity, Applied sciences, Malaria vaccine

You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...

Key Points: 
  • You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...
    OncoSec and researchers at Providence Cancer Institute previously announced a collaboration to conduct a first-in-human trial of OncoSec's CORVax12 vaccine candidate.
  • CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.
  • Researchers believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
  • OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Retrieved on: 
Wednesday, July 1, 2020
Vaccination, Vaccines, Medical specialties, Medicine, Drugs, Vaccine, Virology, Cancer vaccine, Hypothetical technology, Papillomavirus, Agenus, Malaria vaccine

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Retrieved on: 
Wednesday, July 1, 2020
Vaccination, Vaccines, Medical specialties, Medicine, Drugs, Vaccine, Virology, Cancer vaccine, Hypothetical technology, Papillomavirus, Agenus, Malaria vaccine

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Ocean Biomedical Announces Groundbreaking Malaria Vaccine Discovery

Retrieved on: 
Wednesday, April 22, 2020
Vaccines, Medical specialties, Malaria, Hypothetical technology, Medicine, Malaria vaccine, Vaccine, Clinical medicine

PROVIDENCE, R.I., April 22, 2020 /PRNewswire/ --Ocean Biomedical is pleased to announce a groundbreaking discovery in the global effort to eradicate malaria.

Key Points: 
  • PROVIDENCE, R.I., April 22, 2020 /PRNewswire/ --Ocean Biomedical is pleased to announce a groundbreaking discovery in the global effort to eradicate malaria.
  • "Dr. Kurtis' team's discovery of PfGARP is a major advance toward developing a vaccine for this devastating disease, and Ocean Biomedical is committed to developing and delivering this vaccine."
  • Ocean Biomedical is developing Dr. Kurtis' discovery to accelerate the timetable for clinical availability of this new vaccine and related medicines.
  • "This malaria vaccine platform has generated one of the most exciting vaccine candidates for treating malaria in the world.

Global malaria vaccine market is expected to grow with a CAGR of 34% over the forecast period from 2019-2025

Retrieved on: 
Friday, March 13, 2020
Medical specialties, Infectious diseases, Medicine, Malaria, Vaccines, Hypothetical technology, RTT, Malaria vaccine, Vaccine, Forecasting

The report on the global malaria vaccine market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Key Points: 
  • The report on the global malaria vaccine market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report predicts the global malaria vaccine market to grow with a CAGR of 34% over the forecast period from 2019-2025.
  • The study on malaria vaccine market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.
  • The report on malaria vaccine market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global malaria vaccine market over the period of 2017 to 2025.

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Retrieved on: 
Wednesday, March 11, 2020
Infectious diseases, Medical specialties, Medicine, Malaria, Vaccines, Novavax, Hypothetical technology, Malaria vaccine, Adar Poonawalla, Vaccine, Plasmodium falciparum, Serum Institute of India

SII licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum-induced malaria disease, from the Jenner Institute at Oxford University in 2017.

Key Points: 
  • SII licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum-induced malaria disease, from the Jenner Institute at Oxford University in 2017.
  • Matrix-M will be manufactured and supplied to SII by Novavax AB, a wholly-owned subsidiary of Novavax based in Uppsala, Sweden.
  • He commented, It has proven very challenging to develop a vaccine against malaria and many different approaches have been tested.
  • Novavax next-generation adjuvant, Matrix-M, is an impressive and critical component in this much-needed malaria vaccine, said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.